Drugs / MPV/S-2P
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06441968 | Jul 2024 → Nov 2025 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPV/S-2P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06441968 ↗ |
| Modality | Vaccine | “MPV/S-2P SARS-CoV-2 Vaccine” NCT06441968 ↗ |
| Route | Intranasal | “MPV/S-2P administered intranasally” NCT06441968 ↗ |